ExclusivePfizer, Amgen among 22 strategic firms eyeing Hong Kong expansion: source
Sixth batch under investment-attraction initiative to also feature Boehringer Ingelheim, Hengrui and HAYA, with DiDi and AutoFlight joining transport push
Global drug maker Pfizer and biotech firm Amgen, each valued at more than HK$1 trillion (US$153 billion), are among 22 strategic enterprises planning to open or expand offices in Hong Kong, the South China Morning Post has learned.
A source said on Monday that these industry leaders were among companies from the fintech, cloud computing and aerial transport sectors set to sign agreements with the Office for Attracting Strategic Enterprises.
The coming influx of companies will mark the sixth cohort under the government’s flagship investment-attraction initiative since its launch.
Pfizer is a leading global research-based pharmaceutical and biotechnology company. As of April, it has a market capitalisation of HK$1.2 trillion.
Amgen, meanwhile, is one of the world’s largest independent biotechnology companies. It was founded in 1980 and is headquartered in California.
The firm focuses on discovering, developing and delivering human therapeutics for serious illnesses, using advanced human genetics and molecular biology to treat diseases in oncology, cardiology, bone health, inflammation and nephrology.
As of April 2026, Amgen’s market capitalisation is about HK$1.5 trillion.